Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Exclusion Criteria

• •Must not have received an excessive cumulative dose of anthracycline
• •No ≥ grade 2 peripheral neuropathy.
• •No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.
• •No autologous stem cell transplant within 6 months prior to registration for protocol therapy
• •No prior radiation therapy to \> 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.
• •No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.
• •No known central nervous system involvement by myeloma.
• •No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the investigator would limit compliance with study requirements.
• •No patients known to be positive for HIV, or active Hepatitis A, B, or C.
• •No major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed.